{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T03:27:54Z","timestamp":1793935674874,"version":"4.8.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021954","name":"Tour de Cure","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001773","name":"University of New South Wales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001773","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.drudis.2026.104817","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T07:12:17Z","timestamp":1790320337000},"page":"104817","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chemoproteomics in covalent cancer drug discovery"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0985-0517","authenticated-orcid":false,"given":"John-Paul","family":"Ong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7510-1327","authenticated-orcid":false,"given":"Montana","family":"Dalziel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8947-2885","authenticated-orcid":false,"given":"Dona","family":"Johns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6897-6822","authenticated-orcid":false,"given":"Jean","family":"Bertoldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104817_b0005","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/nrd2961","article-title":"Lessons from 60 years of pharmaceutical innovation","volume":"8","author":"Munos","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104817_b0010","first-page":"85","article-title":"2023 FDA approvals","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104817_b0015","doi-asserted-by":"crossref","first-page":"7941","DOI":"10.3390\/molecules28247941","article-title":"Forward or backward: lessons learned from small molecule drugs approved by FDA from 2012 to 2022","volume":"28","author":"Gu","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2026.104817_b0020","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/dta.301","article-title":"Early drug discovery and the rise of pharmaceutical chemistry","volume":"3","author":"Jones","year":"2011","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.drudis.2026.104817_b0025","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1172\/JCI108132","article-title":"The mechanism of the effect of aspirin on human platelets. Acetylation of a particulate fraction protein","volume":"56","author":"Roth","year":"1975","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2026.104817_b0030","first-page":"226","article-title":"On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenz\u00e6","volume":"10","author":"Fleming","year":"1929","journal-title":"Br J Exp Pathol"},{"key":"10.1016\/j.drudis.2026.104817_b0035","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1073\/pnas.54.4.1133","article-title":"Mechanism of action of penicillins: a proposal based on their structural similarity to acyl-D-alanyl-D-alanine","volume":"54","author":"Tipper","year":"1965","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2026.104817_b0040","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0022-3565(25)29664-1","article-title":"Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo","volume":"187","author":"Jollow","year":"1973","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drudis.2026.104817_b0045","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1124\/pharmrev.120.000121","article-title":"The nitrogen mustards","volume":"74","author":"Highley","year":"2022","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.drudis.2026.104817_b0050","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.toxlet.2015.06.012","article-title":"An integrated view of cisplatin-induced nephrotoxicity and ototoxicity","volume":"237","author":"Karasawa","year":"2015","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.drudis.2026.104817_b0055","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd3410","article-title":"The resurgence of covalent drugs","volume":"10","author":"Singh","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104817_b0060","doi-asserted-by":"crossref","first-page":"8361","DOI":"10.1039\/D1CS00231G","article-title":"Chemoproteomic methods for covalent drug discovery","volume":"50","author":"Chan","year":"2021","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.drudis.2026.104817_b0065","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/cmdc.201900107","article-title":"Covalent inhibition in drug discovery","volume":"14","author":"Ghosh","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.drudis.2026.104817_b0070","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1021\/jm901137j","article-title":"New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays","volume":"53","author":"Baell","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104817_b0075","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1021\/ja0455547","article-title":"ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens","volume":"127","author":"Huth","year":"2005","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.drudis.2026.104817_b0080","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1146\/annurev-biochem-060713-035708","article-title":"Enzyme inhibitor discovery by activity-based protein profiling","volume":"83","author":"Niphakis","year":"2014","journal-title":"Ann Rev Biochem"},{"key":"10.1016\/j.drudis.2026.104817_b0085","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.chembiol.2012.01.001","article-title":"How chemoproteomics can enable drug discovery and development","volume":"19","author":"Moellering","year":"2012","journal-title":"Chem Biol"},{"key":"10.1016\/j.drudis.2026.104817_b0090","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/s41573-022-00542-z","article-title":"Advances in covalent drug discovery","volume":"21","author":"Boike","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104817_b0095","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/1078-0432.CCR-21-3074","article-title":"FDA approval summary: sotorasib for KRAS G12C-mutated metastatic NSCLC","volume":"28","author":"Nakajima","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104817_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2023.100164","article-title":"Activity-based protein profiling: a graphical review","volume":"5","author":"Porta","year":"2023","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"10.1016\/j.drudis.2026.104817_b0105","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.chembiol.2023.02.008","article-title":"Chemoproteomics-enabled discovery of a covalent molecular glue degrader targeting NF-\u03baB","volume":"30","author":"King","year":"2023","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.drudis.2026.104817_b0110","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.chembiol.2021.01.005","article-title":"Chemoproteomics-enabled discovery of covalent RNF114-based degraders that mimic natural product function","volume":"28","author":"Luo","year":"2021","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.drudis.2026.104817_b0115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1203073","article-title":"Antibody-drug conjugates: the paradigm shifts in the targeted cancer therapy","volume":"14","author":"Aggarwal","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2026.104817_b0120","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1021\/jasms.5c00204","article-title":"Cysteine reactivity profiling illuminates monoclonal antibody disulfide bond reduction mechanisms in biopharmaceutical process intermediates","volume":"36","author":"Tsukidate","year":"2025","journal-title":"J Am Soc Mass Spect"},{"key":"10.1016\/j.drudis.2026.104817_b0125","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1039\/D3CS00715D","article-title":"Chemical technology principles for selective bioconjugation of proteins and antibodies","volume":"53","author":"Chauhan","year":"2024","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.drudis.2026.104817_b0130","doi-asserted-by":"crossref","first-page":"9367","DOI":"10.1073\/pnas.97.17.9367","article-title":"Site-directed ligand discovery","volume":"97","author":"Erlanson","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2026.104817_b0135","doi-asserted-by":"crossref","first-page":"264a","DOI":"10.1016\/j.bpj.2013.11.1547","article-title":"Covalent Docking of Large Libraries for the Discovery of Chemical Probes","volume":"106","author":"London","year":"2014","journal-title":"Biophys J"},{"key":"10.1016\/j.drudis.2026.104817_b0140","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.copbio.2016.08.003","article-title":"Activity-based protein profiling for mapping and pharmacologically interrogating proteome-wide ligandable hotspots","volume":"43","author":"Roberts","year":"2017","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.drudis.2026.104817_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2023.100164","article-title":"Activity-based protein profiling: a graphical review","volume":"5","author":"Porta","year":"2023","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"10.1016\/j.drudis.2026.104817_b0150","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/513481a","article-title":"Chemistry: chemical con artists foil drug discovery","volume":"513","author":"Baell","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104817_b0155","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/med.22084","article-title":"Advances in reversible covalent kinase inhibitors","volume":"45","author":"Zhao","year":"2025","journal-title":"Med Res Rev"},{"key":"10.1016\/j.drudis.2026.104817_b0160","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1039\/D0CB00222D","article-title":"Fragment-based covalent ligand discovery","volume":"2","author":"Lu","year":"2021","journal-title":"RSC Chem Biol"},{"key":"10.1016\/j.drudis.2026.104817_b0165","doi-asserted-by":"crossref","first-page":"6653","DOI":"10.1021\/acs.chemrev.5c00001","article-title":"Advancing covalent ligand and drug discovery beyond cysteine","volume":"125","author":"Kim","year":"2025","journal-title":"Chem Rev"},{"key":"10.1016\/j.drudis.2026.104817_b0170","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.tips.2023.08.014","article-title":"Covalent fragment approaches targeting non-cysteine residues","volume":"44","author":"Csorba","year":"2023","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.drudis.2026.104817_b0175","doi-asserted-by":"crossref","first-page":"9367","DOI":"10.1073\/pnas.97.17.9367","article-title":"Site-directed ligand discovery","volume":"97","author":"Erlanson","year":"2000","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.drudis.2026.104817_b0180","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41586-024-07318-y","article-title":"Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase","volume":"629","author":"Baltgalvis","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104817_b0185","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104817_b0190","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/s41589-020-0550-9","article-title":"Identification of a potent and selective covalent Pin1 inhibitor","volume":"16","author":"Pinch","year":"2020","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.drudis.2026.104817_b0195","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41589-021-00786-7","article-title":"Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo","volume":"17","author":"Dubiella","year":"2021","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.drudis.2026.104817_b0200","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1021\/acschembio.6b00266","article-title":"Discovery of a selective covalent inhibitor of lysophospholipase-like 1 (LYPLAL1) as a tool to evaluate the role of this serine hydrolase in metabolism","volume":"11","author":"Ahn","year":"2016","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.drudis.2026.104817_b0205","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/s41589-020-0555-4","article-title":"Discovery of small-molecule enzyme activators by activity-based protein profiling","volume":"16","author":"Kok","year":"2020","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.drudis.2026.104817_b0210","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nrd3620","article-title":"The pharmacological landscape and therapeutic potential of serine hydrolases","volume":"11","author":"Bachovchin","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104817_b0215","doi-asserted-by":"crossref","first-page":"14694","DOI":"10.1073\/pnas.96.26.14694","article-title":"Activity-based protein profiling: the serine hydrolases","volume":"96","author":"Liu","year":"1999","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.drudis.2026.104817_b0220","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.drudis.2021.10.021","article-title":"Selectivity aspects of activity-based (chemical) probes","volume":"27","author":"Heinzlmeir","year":"2022","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104817_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112151","article-title":"Activity-based protein profiling: recent advances in medicinal chemistry","volume":"191","author":"Deng","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2026.104817_b0230","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nbt.1531","article-title":"Identification of selective inhibitors of uncharacterized enzymes by high-throughput screening with fluorescent activity-based probes","volume":"27","author":"Bachovchin","year":"2009","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.drudis.2026.104817_b0235","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/1258","article-title":"A retinoblastoma-binding protein that affects cell-cycle control and confers transforming ability","volume":"19","author":"Woitach","year":"1998","journal-title":"Nat Genet"},{"key":"10.1016\/j.drudis.2026.104817_b0240","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s42003-022-04389-3","article-title":"Genome-wide siRNA screens identify RBBP9 function as a potential target in Fanconi anaemia-deficient head-and-neck squamous cell carcinoma","volume":"6","author":"Pai","year":"2023","journal-title":"Commun Biol"},{"key":"10.1016\/j.drudis.2026.104817_b0245","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2174\/092986612799080356","article-title":"Human retinoblastoma binding protein 9, a serine hydrolase implicated in pancreatic cancers","volume":"19","author":"Vorobiev","year":"2012","journal-title":"Protein Pept Lett"},{"key":"10.1016\/j.drudis.2026.104817_b0250","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nbt714","article-title":"Proteomic profiling of mechanistically distinct enzyme classes using a common chemotype","volume":"20","author":"Adam","year":"2002","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.drudis.2026.104817_b0255","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1038\/s41388-024-03096-z","article-title":"GSTO1 aggravates EGFR-TKIs resistance and tumor metastasis via deglutathionylation of NPM1 in lung adenocarcinoma","volume":"43","author":"Shen","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2026.104817_b0260","doi-asserted-by":"crossref","first-page":"16605","DOI":"10.1021\/ja2066972","article-title":"Potent and selective inhibitors of glutathione S-transferase omega 1 that impair cancer drug resistance","volume":"133","author":"Tsuboi","year":"2011","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.drudis.2026.104817_b0265","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/j.bmcl.2010.02.011","article-title":"Oxime esters as selective, covalent inhibitors of the serine hydrolase retinoblastoma-binding protein 9 (RBBP9)","volume":"20","author":"Bachovchin","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104817_b0270","doi-asserted-by":"crossref","first-page":"24075","DOI":"10.1021\/acs.jmedchem.5c01724","article-title":"Discovery of potent, allosteric GSTO1 covalent inhibitors with a new binding mode","volume":"68","author":"Sun","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104817_b0275","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nature18002","article-title":"Proteome-wide covalent ligand discovery in native biological systems","volume":"534","author":"Backus","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104817_b0280","doi-asserted-by":"crossref","first-page":"8951","DOI":"10.1021\/jacs.9b02822","article-title":"Rapid covalent-probe discovery by electrophile-fragment screening","volume":"141","author":"Resnick","year":"2019","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.drudis.2026.104817_b0285","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1002\/anie.201912075","article-title":"Isotopically labeled desthiobiotin azide (isoDTB) tags enable global profiling of the bacterial cysteinome","volume":"59","author":"Zanon","year":"2020","journal-title":"Angew Chem Int Edn"},{"key":"10.1016\/j.drudis.2026.104817_b0290","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0003-2697(02)00201-4","article-title":"Easily reversible desthiobiotin binding to streptavidin, avidin, and other biotin-binding proteins: uses for protein labeling, detection, and isolation","volume":"308","author":"Hirsch","year":"2002","journal-title":"Anal Biochem"},{"key":"10.1016\/j.drudis.2026.104817_b0295","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41587-020-00778-3","article-title":"Reimagining high-throughput profiling of reactive cysteines for cell-based screening of large electrophile libraries","volume":"39","author":"Kuljanin","year":"2021","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.drudis.2026.104817_b0300","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3892\/mmr.2025.13445","article-title":"Pin1 as a central node in oncogenic signaling: Mechanistic insights and clinical prospects (review)","volume":"31","author":"Lei","year":"2025","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.drudis.2026.104817_b0305","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41589-023-01428-w","article-title":"Assigning functionality to cysteines by base editing of cancer dependency genes","volume":"19","author":"Li","year":"2023","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.drudis.2026.104817_b0310","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.chempr.2017.07.009","article-title":"A water-bridged cysteine-cysteine redox regulation mechanism in bacterial protein tyrosine phosphatases","volume":"3","author":"Bertoldo","year":"2017","journal-title":"Chem"},{"key":"10.1016\/j.drudis.2026.104817_b0315","doi-asserted-by":"crossref","first-page":"6144","DOI":"10.1021\/acs.biochem.8b00639","article-title":"Posttranslational chemical mutagenesis: to reveal the role of noncatalytic cysteine residues in pathogenic bacterial phosphatases","volume":"57","author":"Bertoldo","year":"2018","journal-title":"Biochemistry"},{"key":"10.1016\/j.drudis.2026.104817_b0320","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1021\/acscentsci.9b00467","article-title":"Enhancement of the anti-aggregation activity of a molecular chaperone using a rationally designed post-translational modification","volume":"5","author":"Lindstedt","year":"2019","journal-title":"ACS Central Sci"},{"key":"10.1016\/j.drudis.2026.104817_b0325","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1021\/jacs.7b12874","article-title":"Chemo- and regioselective lysine modification on native proteins","volume":"140","author":"Matos","year":"2018","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.drudis.2026.104817_b0330","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1039\/c1sc00185j","article-title":"Methods for converting cysteine to dehydroalanine on peptides and proteins","volume":"2","author":"Chalker","year":"2011","journal-title":"Chem Sci"},{"key":"10.1016\/j.drudis.2026.104817_b0335","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/anie.201106432","article-title":"Conversion of cysteine into dehydroalanine enables access to synthetic histones bearing diverse post-translational modifications","volume":"51","author":"Chalker","year":"2012","journal-title":"Angew Chem Int Edn"},{"key":"10.1016\/j.drudis.2026.104817_b0340","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/cbic.202000870","article-title":"SP3-FAIMS chemoproteomics for high-coverage profiling of the human cysteinome*","volume":"22","author":"Yan","year":"2021","journal-title":"Chembiochem"},{"key":"10.1016\/j.drudis.2026.104817_b0345","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/nchem.2826","article-title":"Global profiling of lysine reactivity and ligandability in the human proteome","volume":"9","author":"Hacker","year":"2017","journal-title":"Nat Chem"},{"key":"10.1016\/j.drudis.2026.104817_b0350","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41557-025-02012-6","article-title":"Global profiling of arginine reactivity and ligandability in the human proteome","volume":"18","author":"Wang","year":"2026","journal-title":"Nat Chem"},{"key":"10.1016\/j.drudis.2026.104817_b0355","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1038\/s41557-023-01281-3","article-title":"Direct mapping of ligandable tyrosines and lysines in cells with chiral sulfonyl fluoride probes","volume":"15","author":"Chen","year":"2023","journal-title":"Nat Chem"},{"key":"10.1016\/j.drudis.2026.104817_b0360","doi-asserted-by":"crossref","first-page":"9297","DOI":"10.1021\/acs.jmedchem.3c00550","article-title":"Expanding chemical probe space: quality criteria for covalent and degrader probes","volume":"66","author":"Hartung","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104817_b0365","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4161\/sgtp.1.1.12178","article-title":"Ras history","volume":"1","author":"Cox","year":"2010","journal-title":"Small GTPases"},{"key":"10.1016\/j.drudis.2026.104817_b0370","doi-asserted-by":"crossref","first-page":"re13","DOI":"10.1126\/stke.2502004re13","article-title":"Human RAS superfamily proteins and related GTPases","volume":"2004","author":"Colicelli","year":"2004","journal-title":"Sci STKE"},{"key":"10.1016\/j.drudis.2026.104817_b0375","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","article-title":"KRAS inhibitors: resistance drivers and combinatorial strategies","volume":"11","author":"Isermann","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.drudis.2026.104817_b0380","first-page":"1","article-title":"Targeting KRAS in pancreatic cancer: new drugs on the horizon","author":"Bannoura","year":"2021","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.drudis.2026.104817_b0385","doi-asserted-by":"crossref","first-page":"6630","DOI":"10.18632\/oncotarget.23553","article-title":"Implications of KRAS mutations in acquired resistance to treatment in NSCLC","volume":"9","author":"Del Re","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2026.104817_b0390","article-title":"Current strategies and future dimensions in the development of KRAS inhibitors for targeted anticancer therapy","volume":"86","author":"D\u2019Alessio-Sands","year":"2025","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.drudis.2026.104817_b0395","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-ND03","article-title":"Abstract ND03: discovery of RMC-9805, an oral, covalent tri-complex KRASG12D(ON) inhibitor","volume":"84","author":"Knox","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2026.104817_b0400","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2026.104817_b0405","doi-asserted-by":"crossref","first-page":"11214","DOI":"10.3390\/ijms252011214","article-title":"Proteolysis targeting chimera agents (PROTACs): new hope for overcoming the resistance mechanisms in oncogene-addicted non-small cell lung cancer","volume":"25","author":"Cordani","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104817_b0410","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","article-title":"PROteolysis TArgeting Chimeras (PROTACs) \u2013 past, present and future","volume":"31","author":"Pettersson","year":"2019","journal-title":"Drug Discov Today Technol"},{"key":"10.1016\/j.drudis.2026.104817_b0415","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In vivo activation of the p53 pathway by small-molecule antagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.drudis.2026.104817_b0420","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.chembiol.2017.09.010","article-title":"Lessons in PROTAC design from selective degradation with a promiscuous warhead","volume":"25","author":"Bondeson","year":"2018","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.drudis.2026.104817_b0425","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1021\/acscentsci.0c00411","article-title":"Targeted degradation of oncogenic KRASG12C by VHL-recruiting PROTACs","volume":"6","author":"Bond","year":"2020","journal-title":"ACS Central Sci"},{"key":"10.1016\/j.drudis.2026.104817_b0430","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41589-024-01821-z","article-title":"Implications of frequent hitter E3 ligases in targeted protein degradation screens","volume":"21","author":"Zhang","year":"2025","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.drudis.2026.104817_b0435","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.chembiol.2021.03.005","article-title":"The role of reversible and irreversible covalent chemistry in targeted protein degradation","volume":"28","author":"Kiely-Collins","year":"2021","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.drudis.2026.104817_b0440","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1039\/D3SC06558H","article-title":"Discovery of potent PROTAC degraders of Pin1 for the treatment of acute myeloid leukemia","volume":"15","author":"Shi","year":"2024","journal-title":"Chem Sci"},{"key":"10.1016\/j.drudis.2026.104817_b0445","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1021\/acschembio.8b01094","article-title":"PROTAC-mediated degradation of Bruton\u2019s tyrosine kinase is inhibited by covalent binding","volume":"14","author":"Tinworth","year":"2019","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.drudis.2026.104817_b0450","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.chembiol.2024.04.002","article-title":"Molecular glues for protein-protein interactions: Progressing toward a new dream","volume":"31","author":"Konstantinidou","year":"2024","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.drudis.2026.104817_b0455","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1158\/2159-8290.CD-25-1187","article-title":"A covalent allosteric molecular glue suppresses NRF2-dependent cancer growth","volume":"16","author":"Roy","year":"2026","journal-title":"Cancer Discov"},{"key":"10.1016\/j.drudis.2026.104817_b0460","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nchembio.1060","article-title":"Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis","volume":"8","author":"Anastasiou","year":"2012","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.drudis.2026.104817_b0465","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"10.1016\/j.drudis.2026.104817_b0470","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.2174\/0929867331666230714144851","article-title":"Recent advances on PKM2 inhibitors and activators in cancer applications","volume":"31","author":"Chen","year":"2024","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.drudis.2026.104817_b0475","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1016\/j.bmcl.2010.04.015","article-title":"Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase","volume":"20","author":"Jiang","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104817_b0480","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1021\/jm901577g","article-title":"Evaluation of substituted N,N\u2032-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase","volume":"53","author":"Boxer","year":"2010","journal-title":"J Med Chem"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T03:07:25Z","timestamp":1793934445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626002229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":96,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1359644626002229"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104817","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemoproteomics in covalent cancer drug discovery","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104817","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104817"}}